GRI Bio, Inc.
GRI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001824293
No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.
Q2 2026 vs. Q1 2026
How the institutions holding GRI Bio, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 6 | 11 | +5 |
| Shares | 28.2K | 93.6K | +65.3K (+231.5%) |
| Value | $64.7K | $164.7K | +$100.0K (+154.7%) |
New holders (6)
Institutions that held GRI Bio, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| HRT Financial LP | 28,784 | $50.0K | 0.00% |
| Vanguard Capital Management LLC | 21,368 | $37.8K | 0.00% |
| Citadel Advisors LLC | 13,376 | $23.7K | 0.00% |
| Morgan Stanley | 8,737 | $15.5K | 0.00% |
| Barclays PLC | 83 | $147 | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | $4 | 0.00% |
Sold out (1)
Institutions that held GRI Bio, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| SBI Securities Co., Ltd. | 4 | $9 |